FindTrial
Sign In

Sequential ASCT and CAR-T treatment for R/R NHL: A Multicenter Real-World Study on the Choice of CAR-T Timing and Conjugation therapy

Sequential ASCT and CAR-T treatment for R/R NHL: A Multicenter Real-World Study on the Choice of CAR-T Timing and Conjugation therapy - The Real-World Study of Sequential CAR-T Therapy Following Autologous Stem Cell Transplantation

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500098577
Enrollment
Unknown
Registered
2025-03-11
Start date
2025-05-01
Completion date
Unknown
Last updated
2025-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-Hodgkin's lymphoma

Interventions

Case series:N/A

Sponsors

The First Affiliated Hospital of Soochow University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: (1) Patients with a confirmed lymphoma diagnosis based on pathological biopsy results. (2) Patients who have received CAR-T therapy, with or without prior autologous hematopoietic stem cell transplantation. (3) Patients with complete clinical data.

Exclusion criteria

Exclusion criteria: (1) Primary diagnosis of a non-hematologic disease. (2) Life expectancy shorter than the study duration due to other non-hematologic conditions. (3) Age below 18 years or above 90 years.

Design outcomes

Primary

MeasureTime frame
complete remission rate;All cause mortality;—

Secondary

MeasureTime frame
partial remission rate;Cytokine Release Syndrome;Immune Effector Cell Associated Neurotoxicity Syndrome;overall survival;progressive free survival time;—

Countries

China

Contacts

Public ContactHaiwen Huang

Department of Hematology, The First Affiliated Hospital of Soochow University

huanghaiwen@suda.edu.cn+86 512 6778 1856

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026